An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Safety evaluations including but not limited to adverse events/serious adverse events, safety laboratory parameters, vital signs, etc., through End of Study visit

Response defined as maintaining sustained hemoglobin levels ≥ 12 g/dL in the absence of transfusions evaluated over yearly follow up intervals, Absence of administration of packed-red blood cell transfusions evaluated over yearly follow up intervals, Occurrences of breakthrough hemolysis and of Major Adverse Vascular Events, MAVE occurring evaluated over yearly follow up intervals

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Czechia, France, Germany, Italy, Lithuania, Netherlands, Spain